Диссертация (1140113), страница 16
Текст из файла (страница 16)
2009; 84:5: 436—445.132.Buse D.C. Sociodemographic and comorbidity profiles of chronic migraine andepisodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010; 428-432.133.Buse D.C., Manack A.N., Serrano D., Reed M., Varon S., Turkel C., Lipton R.Headache impact of chronic and episodic migraine: results from the American MigrainePrevalence and Prevention study. Headache. 2012; 52: 1:3—17.134.Buse D.C., Manack A., Serrano D., Turkel C., Lipton R.B.
Sociodemographic andcomorbidity profiles of chronic migraine and episodic migraine sufferers. J NeurolNeurosurg Psychiatry. 2010; 81: 428—432.135.Buse D.C., Rupnow M.F., Lipton R.B. Assessing and managing all aspects ofmigraine: migraine attacks, migraine-related functional impairment, common comorbidities,and quality of life. Mayo Clin Proc 2009; 84:422–435.136.Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatriccomorbidities of episodic and chronic migraine. J Neurol. 2013;260(8):1960-9.137.Cady R.K., Schreiber C.P. Sinus problems as cause of headache refractoriness andmigraine chronification.
Curr Pain Headache Rep 2009; 13:319-325.138.Calvert M. J., Freemantle N. Use of health-related quality of life in prescribingresearch. Part 1: why evaluate health-related quality of life? Journal of Clinical Pharmacyand Therapeutics. 2003; 28: 6: 513—521.139. .Chiarugi A.Overuse of Headache Medications: from Neurochemistry toPathophysiology. Clinical and Preclinical Clues. J Headache Pain. 2017; 18(Suppl 1): 111.S44.140.Cousins G. Diagnostic Accuracy of the ID Migraine: A Systematic Review andMeta-Analysis.
The Journal of Head and Face Pain. 2011; № 7; 1140-1148.141.D'Amico D,Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, et al. TheMigraine Disability Assessment (MIDAS) questionnaire: translation and reliability of theItalian version. Cephalalgia 2001;21:947–52.97142. D'AmicoD., Solari A., Usai S. Improvement in quality of life and activity limitations inmigraine patients after prophylaxis. A prospective longitudinal multicentre study.Cephalalgia.
2006. Vol.26. P. 691-696.143.D’Amico D., Grazzi L, Usai S, Raggi A, Leonardi M, Bussone G . Disability inchronic daily headache: state of the art and future directions. Neurol Sci. 2011. 32:S71–S76.144.D’Amico D., Curone M., Tullo V. et al. Polytherapy for the prophylaxis ofchronic migraine: an Italian survey. Neurol. Sci. – 2011; 32 (Suppl 1): S185–S188.145. D'AmicoD, Grazzi L, Bussone G, Curone M, Di Fiore P, Usai S, Leonardi M,Giovannetti AM, Schiavolin S, Raggi A. Are depressive symptomatology, self-efficacy, andperceivedsocialsupportrelatedtodisabilityand qualityoflife inpatientswith chronic migraine associated to medication overuse? Data from a cross-sectional study.Headache.
2015 May;55(5):636-45.146.D'Amico D, Leonardi M, Grazzi L, Curone M, Raggi A. Disability and quality of life inpatients with different forms of migraine. J Headache Pain. 2015 Dec;16(Suppl 1):A4.147.De Tommaso M., Delussi M., Vecchio E., Sciruicchio V., Invitto S., Livrea P.Sleep features and central sensitization symptomsin primary headache patients. TheJournal of Headache and Pain. 2014; 15:64.148. DiLorenzo C., Ienca R., Sodano S., Coppola G., Pierelli F.
Application of “very low-calorie ketogenic diet” in migraine treatment. J Headache Pain. 2017; 18(Suppl 1): 111.S41.149.Diamond M., Dahlof C., Papadopoulos G. Topiramate improves health-relatedquality of life when used to prevent migraine. Headache. 2005.
Vol.45,№8. P.1023-30.150.Diener H.C., Dodick D.W., Goadsby P.J., Lipton R.B., Olesen J., Silberstein S.D.Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol. 2012; 8: 3:162—171.151.Diener H.C., Limmroth V. Medication-overuse headache: a worldwide problem.Lancet Neurol 2004; 3:475-483.98152.Diener H.C., Limmroth V., Katsarava Z. Medical-Overused Headache.In: Chronic daily headache for clinicians, Goadsby P.J., Dodick D.W. (Eds). Decker,Hamilton. 2005; 117p.153.Diener HC, Solbach K, Holle D, Gaul C.
Integrated care for chronic migraine patients:epidemiology, burden, diagnosis and treatment options. Clin Med (Lond). 2015;15(4):34450.154.Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, LiptonRB. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: resultsfrom the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 2016;56(5): 821–834.155.Domingues R., Silva A.L., Domingues S.A. et al. A double-blind randomizedcontrolled trial of low dose of propranolol, nortrypiline, and the combination of propranololand nortryptiline for the preventive treatment of migraine/ Arq. Neuropsiquiatr 2009; 67(4):973–977.156.Dougherty C, Silberstein SD. Providing Care for Patients with Chronic Migraine:Diagnosis, Treatment, and Management.
Pain Pract. 2015;15(7):688-92.157.Duru G., Michel P., Pariente P. MIG ACCESS: a population- based, nationwide,comparative survey of access to care in migraine in France. Cephalalgia. 1996; 16:50-5.158.El Hasnaoui A, Vray M, Blin P. et al. Assessment of migraine severity using theMIGSEV scale: relationship to migraine features and quality of life. Cephalalgia. 2004. Vol.24(4). Р. 262-270.159.Evers S., Marziniak M.
Clinical features, pathophysiology and treatment ofmedication-overuse headache. Lancet Neurol 2010; 9:391-401.160.EuroQol – a new facility for the measurement of health related quality of life.The EuroQol group. Health Policy, 1990; 16: 199-208.161.Fairclaugh L.D. Design and Analysis of Quality of Life Studies in Clinical Trials.Charman & Hall/ CRC. 2002.
- P. 164-177.162.Ferrari A., Leone S., Vergoni A.V. et al. Similarities and differences betweenchronic migraine and episodic migraine. Headache. 2007; 47: 1: 65—72.99163.Filatova E, Latysheva N, Kurenkov A. Evidence of persistent central sensitization inchronic headaches: a multi-method study. J Headache Pain. 2008; 9(5):295-300.164.Garza I, Schwedt TJ.
Diagnosis and management of chronic daily headache. SeminNeurol. 2010; 30(2): 154-166.165.Garcia-Monco J.C. , Foncea N., Bilbao A. Impact of preventive therapy withnadolol and topiramate on the quality of life of migraine patients. Cephalalgia. 2007. V.27(8). P. 920-928.166.Global, regional, and national age–sex specific all-cause and cause-specificmortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burdenof Disease Study 2015.
Lancet 2015; 385(9963): 117-171.167.Gunreben-Stempfle B., Griessinger N., Lang E. et al. Effectiveness of anintensive multidisciplinary treatment of headache. Headache 2009; 49(7):990-1000.168.Halker R.B., Hastriter E.V., Dodick D.W. Chronic daily headache: an evidence-based and systematic approach to a challenging problem. Neurology 2011; 76: 37-43.169.Harpole L.H., Samsa G.P., Jurgelski A.E.
et al. Headache management programimproves outcome for chronic headache. Headache 2003; 43:715-724.170.Hartmaier S.L., Santanello N.C., Epstein R.S., Silberstein S.D. Development of abrief 24-hour migraine-specific quality of life questionnaire. Headache.1995; 35: 6: 320—329.171.Headache Classification Subcommittee, International Headache Society. Theinternational classification of headache disorders, 2nd edition. Cephalalgia.
2004; 24: 1: 1—160.172.Headache Classification Committee of the International Headache Society. TheInternational Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia.2013; 33(9): 629-808.173.Headache Classification Committee of the International Headache Society. TheInternational Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211.100174.Hornquist J.O. The concept of quality of life. Scand. J. Soc. Med.
1982. Vol.10. P.57-61.175.Jensen R., Zeeberg P., Dehlendorff C. et al. Predictors of outcome of thetreatment programme in a multidisciplinary headache centre. Cephalalgia 2010; 30:12141224.176.Jhingran P., Osterhaus J. T., Miller D., Lee J.T., Kirchdoerfer L. Development andvalidation of the migraine-specific quality of life questionnaire.
Headache. 1998; 38: 4: 295—302.177.Katsarava Z. Chronic migraine: Classification and comparisons. Cephalalgia.2011; 520-529.178.Katsarava Z., Dzagnidze A., Kukava M. et al. Primary headache disorders in theRepublic of Georgia: Prevalence and risk factors. Neurology. 2009; 73:1796-803.179.Katsarava Z., Jensen R.
Medication-overuse headache: where are we now? CurrOpin Neurol. 2007; 20: 3: 326—330.180.Katsarava Z., Manack A., Yoon M.S., Obermann M., Becker H., Dommes P.,Turkel C., Lipton R.B., Diener H.C. Chronic migraine: classification and comparisons.Cephalalgia. 2011; 520—529.181.Keefe F.J., Brown C, Scott D., Ziesat H. Behavioral assessment of chronic pain.In: F.J. Keefe, and J. Blumenthal (Eds.), Assessment Strategies in Behavioral Medicine.New York: Grune and Stratton. 1982.182.Kerns R.D., Turk D.S., Rudy Т.Е. The West Haven-Yale Multidimensional PainInventory (WHYMPI).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
